Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Lung04: Dato-DXd + Immunotherapy +/- Carboplatin in Advanced/Metastatic NSCLC
NCT04612751Phase 1Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2021
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 8
01
Overview
Phase 1, open-label trial of datopotamab deruxtecan in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Feb 2021; status: active, not recruiting.
02
Drugs
datopotamab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04612751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04612751.